<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2415">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04367883</url>
  </required_header>
  <id_info>
    <org_study_id>02-20-161-021</org_study_id>
    <nct_id>NCT04367883</nct_id>
  </id_info>
  <brief_title>Influenza Vaccination, ACEI and ARB in the Evolution of SARS-Covid19 Infection</brief_title>
  <official_title>Evaluation of Influenza Vaccination and Treatment With ACEI and ARB in the Evolution of SARS-Covid19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Consorci Sanitari de Terrassa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jordi Gol i Gurina Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Català de la Salut</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Consorci Sanitari de Terrassa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Some authors have proposed the use of the flu vaccine to reduce the severity of COVID-19
      cases, while some have proposed the use of ACE Inhibitors (ACEI) or Angiotensin Receptor
      blockers (ARB), since this virus shares hemagglutinin as a transmission mechanism and acts on
      the ACE2 enzyme during infection.

      The aim is to evaluate whether the admitted patients who are previously vaccinated or those
      who were already receiving treatment show a better evolution.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The number of patients admitted at the hospital, their comorbidity (Charlson index), the
      number of previous treatments, the length of admission, the need or not of the Intensive Care
      Unit (ICU) and their final status (survivors or non survivors) would be studied.

      If patients that previously received the influenza vaccine or treated with ACEI or ARB showed
      a better evolution, it would be proposed to extend vaccination and the inclusion of ACE
      inhibidors and ARB in the treatment of infection.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>hospital output</measure>
    <time_frame>from March 1, 2020.</time_frame>
    <description>exitus vs hospital output</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hospital stay</measure>
    <time_frame>From March 1, 2020.</time_frame>
    <description>lenght of the hospital stay</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2574</enrollment>
  <condition>COVID19</condition>
  <condition>Influenza Vaccination</condition>
  <condition>ACE Inhibitors</condition>
  <condition>ARB</condition>
  <arm_group>
    <arm_group_label>CST Hospital Incomes</arm_group_label>
    <description>Observation of patient characteristics of hospital incomes in Hospital of Terrassa from March 1, 2020.
No intervention is performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACE inhibitor</intervention_name>
    <description>If evolution is favorable in patients treated with ACE as assessed at the first step of the study, this treatment would be added in a random selection of new admitted patients suffering Covid19, and results would be compared to a control group of admitted patients.</description>
    <arm_group_label>CST Hospital Incomes</arm_group_label>
    <other_name>ACE inhibitors to treat COVID19 infection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARB</intervention_name>
    <description>If evolution is favorable in patients treated with ARB as assessed at the first step of the study, this treatment would be added in a random selection of new admitted patients suffering Covid19, and results would be compared to a control group of admitted patients.</description>
    <arm_group_label>CST Hospital Incomes</arm_group_label>
    <other_name>ARB to treat COVID10 infection.</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All hospital admissions in the Hospital of Terrassa from March 1, 2020 were innitially
        included.

        Population of reference: the population assigned to the Terrassa Health Consortium
        population.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hospital Admissions at the Hospital of Terrassa from March 1, 2020 for any cause.

        Exclusion Criteria:

          -  None.

          -  For comparison of percentage of Influenza vaccination, ACEI and ARB vs general
             population, patients from outsite the reference area of the Terrassa Health Consortium
             would be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Puigdellívol-Sánchez, Ph D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Consorci Sanitari de Terrassa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna Puigdellívol-Sánchez, Ph.D.</last_name>
    <phone>34-93-5884555</phone>
    <email>apuigdellivol@cst.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mar Muñoz</last_name>
    <phone>34-93-7003657</phone>
    <phone_ext>1895</phone_ext>
    <email>Reserca@cst.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08227</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Puigdellívol-Sánchez, Ph.D.</last_name>
      <phone>34-93-5884555</phone>
      <email>apuigdellivol@cst.cat</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020 Aug;81(5):537-540. doi: 10.1002/ddr.21656. Epub 2020 Mar 4.</citation>
    <PMID>32129518</PMID>
  </reference>
  <results_reference>
    <citation>Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A systematic review. J Med Virol. 2020 May;92(5):479-490. doi: 10.1002/jmv.25707. Epub 2020 Mar 3.</citation>
    <PMID>32052466</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>April 28, 2020</study_first_submitted>
  <study_first_submitted_qc>April 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2020</study_first_posted>
  <last_update_submitted>August 19, 2020</last_update_submitted>
  <last_update_submitted_qc>August 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Consorci Sanitari de Terrassa</investigator_affiliation>
    <investigator_full_name>Anna Puigdellívol-Sánchez</investigator_full_name>
    <investigator_title>M.D., Ph.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

